The average discounted lifetime HIV-related medical cost is approximately $420,000 per person, with antiretroviral therapy accounting for roughly 74% of that total. Annual wholesale acquisition costs for first-line regimens now run about $23,000 to $39,000, having nearly doubled over the preceding decade, and every guideline-recommended initial regimen exceeds $36,000 per year at list price. The clinical picture is shifting alongside the spend: 38% of people with HIV were 55 or older in 2022, older adults accounted for one in six new diagnoses, and more than half of those newly diagnosed presented at a late stage with CD4 counts below 350 cells per microliter.
AAVBC's HIV/AIDS Medication Treatment Utilization Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering regimen selection across eight clinical scenarios from treatment-naive to virologic failure, contraindications, four essential pretreatment checks, drug interaction management, dose and duration recommendations, regimen simplification and de-escalation, virologic failure workup, on-treatment monitoring of aging organ systems, statin therapy for ASCVD prevention, cost-smart prescribing with assistance pathways, and PCP versus specialist responsibilities. Grounded in the current DHHS/OARAC antiretroviral guidelines and peer-reviewed literature, this guide supports consistent, individualized clinical decision-making, helping care teams treat comorbidity rather than virology alone, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of HIV/AIDS medication — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
The average discounted lifetime HIV-related medical cost is approximately $420,000 per person, with antiretroviral therapy accounting for roughly 74% of that total. Annual wholesale acquisition costs for first-line regimens now run about $23,000 to $39,000, having nearly doubled over the preceding decade, and every guideline-recommended initial regimen exceeds $36,000 per year at list price. The clinical picture is shifting alongside the spend: 38% of people with HIV were 55 or older in 2022, older adults accounted for one in six new diagnoses, and more than half of those newly diagnosed presented at a late stage with CD4 counts below 350 cells per microliter.
AAVBC's HIV/AIDS Medication Treatment Utilization Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering regimen selection across eight clinical scenarios from treatment-naive to virologic failure, contraindications, four essential pretreatment checks, drug interaction management, dose and duration recommendations, regimen simplification and de-escalation, virologic failure workup, on-treatment monitoring of aging organ systems, statin therapy for ASCVD prevention, cost-smart prescribing with assistance pathways, and PCP versus specialist responsibilities. Grounded in the current DHHS/OARAC antiretroviral guidelines and peer-reviewed literature, this guide supports consistent, individualized clinical decision-making, helping care teams treat comorbidity rather than virology alone, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of HIV/AIDS medication — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
